CGA
MRNA icon

Crescent Grove Advisors’s Moderna MRNA Stock Holding History

Crescent Grove Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,312
Closed -$201K – 305
2023
Q1 		$201K Sell
1,312
-74
-5% -$12.2K 0.02% 272
2022
Q4 		$249K Sell
1,386
-500
-27% -$81.8K 0.03% 246
2022
Q3 		$223K Buy
1,886
+350
+23% +$53.1K 0.03% 237
2022
Q2 		$219K Buy
1,536
+150
+11% +$21.4K 0.02% 237
2022
Q1 		$239K Buy
+1,386
New +$233K 0.02% 259
2021
Q4 		– Sell
-902
Closed -$347K – 300
2021
Q3 		$347K Buy
902
+22
+3% +$8.11K 0.04% 190
2021
Q2 		$207K Buy
+880
New +$157K 0.02% 246

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Crescent Grove Advisors's MRNA Position: Q2 2023 in Review

Crescent Grove Advisors sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,312 shares — an estimated $201K sold.

Crescent Grove Advisors first reported a position in MRNA in Q2 2021 and held it in 7 quarters. The position peaked at $347K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Crescent Grove Advisors reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Crescent Grove Advisors sold 1,312 Moderna shares in Q2 2023, an estimated $201K.
  • Crescent Grove Advisors first reported a position in Moderna in Q2 2021 and held it in 7 quarters.
  • Crescent Grove Advisors's Moderna position peaked at $347K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Crescent Grove Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.